The wave of AI is accelerating the transformation of the global pharmaceutical industry. AI startup therapiAI announced today (Feb 9) the completion of a Phase 1 AI Proof of Concept (POC) with Panlabs, a world-class leader in biotechnology. Focusing on the optimization of microbial fermentation processes, the collaboration not only identified key factors influencing the process but also successfully established a high-accuracy AI model for predicting fermentation yields. This milestone signifies that the field of microbial R&D is accelerating its embrace of AI, moving toward an AI-empowered era where AI capability will become the decisive factor in global biotech competition.
Mr. Hu, General Manager of Panlabs, stated: “The AI model developed in collaboration with therapiAI accurately analyzes key process parameters and optimal operating ranges. This allows us to truly implement data-driven R&D, which, when complemented by our team’s professional expertise, enables us to solve daily R&D bottlenecks more effectively. Furthermore, the model significantly reduces the frequency of trial and error, enhancing overall R&D efficiency and quality stability.”
According to a report by PwC, AI is poised to generate substantial operational value for the biopharmaceutical industry, potentially creating an additional USD 254 billion in operating profit by 2030. Operations optimization stands as the primary application scenario (39%), followed by R&D efficiency (26%) and commercialization (24%). PwC further notes that beyond 2030, the depth of AI adoption will significantly widen the competitive gap; the disparity between market leaders and followers will be distinctly reflected in revenue performance and value chain integration capabilities. Clearly, AI adoption has become the critical path for industrial upgrading and competitive advantage.
Michael Han, CEO of therapiAI, stated: “The AI-driven R&D paradigm has become a prevailing trend across microbial, large molecule, small molecule, and cell therapies. The core value of AI lies in its ability to transform the invaluable knowledge and experience of domain experts into digital models capable of iterative simulation and validation. This not only effectively preserves domain knowledge but also significantly reduces experimental operational time and raw material costs, ultimately accelerating time-to-market.
In collaborating with the Panlabs team to explore AI Agent applications, therapiAI’s model has demonstrated exceptional adaptability and feasibility. The platform processes complex, multi-modal experimental data, enabling the team to precisely identify key factors influencing yield and facilitate intelligent decision-making. Tailored for the biotech CDMO sector with the potential of a “General Purpose Model,” it addresses the legacy challenges of heavy reliance on individual expert intuition and the difficulty of knowledge transfer. Furthermore, it delivers breakthroughs in resolving critical pain points such as complex parameter tuning, prolonged trial-and-error cycles, and high training costs, comprehensively improving product delivery timelines and quality stability.
The success of this proof-of-concept (POC) lays a solid foundation for future collaboration. Both parties have initiated research into image recognition for microbial morphology, aiming to accelerate strain screening and production workflows through advanced image analysis. Panlabs is also set to launch a comprehensive data inventory and assessment initiative as the starting point for the next phase. This move demonstrates its ambition and execution capability in pioneering AI adoption and leading the industry’s digital transformation.
Having already established successful applications in large molecule pharmaceuticals, cell therapy, and regenerative medicine, therapiAI has now effectively expanded into the microbial R&D sector, demonstrating high technical versatility. Looking ahead, therapiAI will continue to expand into scenarios such as strain breeding, production efficiency prediction, and quality control. This strategy aims to deepen its footprint in the biotech industry and accelerate the full-scale deployment of AI-driven intelligent manufacturing.
